Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

Xiang Chen(St. Jude Children's Research Hospital), Armita Bahrami(St. Jude Children's Research Hospital), Alberto S. Pappo(St. Jude Children's Research Hospital), John Easton(St. Jude Children's Research Hospital), James Dalton(St. Jude Children's Research Hospital), Erin Hedlund(St. Jude Children's Research Hospital), David W. Ellison(St. Jude Children's Research Hospital), Sheila Shurtleff(St. Jude Children's Research Hospital), Gang Wu(St. Jude Children's Research Hospital), Lei Wei(St. Jude Children's Research Hospital), Matthew Parker(St. Jude Children's Research Hospital), Michael Rusch(St. Jude Children's Research Hospital), Panduka Nagahawatte(St. Jude Children's Research Hospital), Jianrong Wu(St. Jude Children's Research Hospital), Shenghua Mao(St. Jude Children's Research Hospital), Kristy Boggs(St. Jude Children's Research Hospital), Heather L. Mulder(St. Jude Children's Research Hospital), Donald Yergeau(St. Jude Children's Research Hospital), Charles Lu(Washington University in St. Louis), Li Ding(Washington University in St. Louis), Michael N. Edmonson(St. Jude Children's Research Hospital), Chunxu Qu(St. Jude Children's Research Hospital), Jianmin Wang(St. Jude Children's Research Hospital), Yongjin Li(St. Jude Children's Research Hospital), Fariba Navid(St. Jude Children's Research Hospital), Najat C. Daw(The University of Texas MD Anderson Cancer Center), Elaine R. Mardis(Washington University in St. Louis), Richard K. Wilson(Washington University in St. Louis), James R. Downing(St. Jude Children's Research Hospital), Jinghui Zhang(St. Jude Children's Research Hospital), Michael A. Dyer(St. Jude Children's Research Hospital)
Cell Reports
April 1, 2014
Cited by 756Open Access
Full Text

Abstract

Pediatric osteosarcoma is characterized by multiple somatic chromosomal lesions, including structural variations (SVs) and copy number alterations (CNAs). To define the landscape of somatic mutations in pediatric osteosarcoma, we performed whole-genome sequencing of DNA from 20 osteosarcoma tumor samples and matched normal tissue in a discovery cohort, as well as 14 samples in a validation cohort. Single-nucleotide variations (SNVs) exhibited a pattern of localized hypermutation called kataegis in 50% of the tumors. We identified p53 pathway lesions in all tumors in the discovery cohort, nine of which were translocations in the first intron of the TP53 gene. Beyond TP53, the RB1, ATRX, and DLG2 genes showed recurrent somatic alterations in 29%-53% of the tumors. These data highlight the power of whole-genome sequencing for identifying recurrent somatic alterations in cancer genomes that may be missed using other methods.


Related Papers

No related papers found

Powered by citation graph analysis